DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,118,655 | +107.3% | 36,755 | +100.5% | 0.11% | +58.3% |
| Q2 2023 | $4,399,463 | -11.4% | 18,331 | -6.9% | 0.07% | -15.3% |
| Q1 2023 | $4,963,930 | -8.4% | 19,695 | -3.5% | 0.08% | -19.0% |
| Q4 2022 | $5,418,564 | +6.3% | 20,415 | +3.6% | 0.10% | -7.9% |
| Q3 2022 | $5,096,000 | +4.6% | 19,705 | +2.6% | 0.11% | +10.7% |
| Q2 2022 | $4,874,000 | -61.9% | 19,209 | -56.0% | 0.10% | -41.5% |
| Q1 2022 | $12,804,000 | +147.4% | 43,650 | +177.5% | 0.18% | +30.4% |
| Q4 2021 | $5,175,000 | +16.1% | 15,728 | +7.4% | 0.14% | +22.7% |
| Q3 2021 | $4,459,000 | +62.1% | 14,645 | +42.9% | 0.11% | +13.4% |
| Q2 2021 | $2,751,000 | +245.2% | 10,252 | +190.1% | 0.10% | +98.0% |
| Q1 2021 | $797,000 | -9.8% | 3,534 | -11.3% | 0.05% | -18.3% |
| Q4 2020 | $884,000 | +90.9% | 3,982 | +85.1% | 0.06% | +33.3% |
| Q3 2020 | $463,000 | -8.9% | 2,151 | -25.2% | 0.04% | -11.8% |
| Q2 2020 | $508,000 | +100.0% | 2,877 | +56.8% | 0.05% | +27.5% |
| Q1 2020 | $254,000 | – | 1,835 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |